Major trends disrupting clinical trials
This is a bonus edition of PharmaVoice’s daily newsletter. Today we’re exploring how elements from AI to diversity initiatives are impacting clinical trial operations. Sign up here to receive insights on the biggest trends and voices in the life sciences industry in your inbox every morning.
Conversations about artificial intelligence and clinical trial diversity are dominating the room at the Drug Information Association’s annual meeting this week in Boston. And how could they not?
Both are leading trends in the life sciences with the potential to transform the way companies conduct R&D and improve health outcomes. They’re also uniquely intertwined; progress in one could affect positive change for the other.
Courtney Granville, director of scientific affairs at DIA, put it this way: “We have to have diversity in our datasets in order to really realize the power of AI.” At the same time, AI technology could also help clinical trial recruiters find more diverse pools of participants.
It’s clear the industry’s push to incorporate more AI processes into clinical trial operations will have real-world consequences on diversity initiatives, but pharma will need to work on both fronts in tandem, Granville argued.
“There is a need to guide the entire industry around the level of transparency that's needed, and around how we can overcome bias in terms of the data,” she said. “Where we could have the largest impact in terms of regulatory guidance is understanding what's needed in terms of diversity.”
Here, we’re looking at how the industry and regulators are dealing with these questions and other major clinical trial trends.
Marwan Fathallah came onboard earlier this year to lead the organization into an era of change.
Recent FDA guidance aims to bolster DCT adoption but provides little clarity on the patchwork of telemedicine laws that pose an obstacle to the approach.
Walgreens leaders are not deterred and hope to fill the holes left behind by the pharmacy giant.
Pharma’s missing the mark when it comes to recruiting Black patients, and Ricki Fairley, CEO of The Black Breast Cancer Alliance, reveals what’s needed.
This is just a sampling of PharmaVoice’s coverage. For more insights into the biggest trends and voices swaying the life sciences industry, be sure to check out our daily newsletter.